Estrogen Patch Supply Increases Following Demand Spike
Manufacturers are ramping up production as prescriptions for estrogen therapy have doubled since early 2025.
Updated on Oct. 21, 2026 in Women’s Health
Live Poll
Should pharmaceutical companies be required to maintain specific supply levels for essential medications during demand spikes?
The United States is seeing a surge in demand for estrogen patches, with prescriptions doubling to 3.6 million between January 2025 and June 2026. In response to this rising need and a February 2026 FDA labeling update, generic drug manufacturers have increased production and reallocated global supply stocks.
Why it matters
The increased demand for estrogen therapy follows updated FDA labeling in February 2026, which has shifted how patients and providers approach hormone treatment. Manufacturers are now scaling production to improve supply chain resilience, though they note that complex transdermal systems remain difficult for compounding entities to replicate.
Data analysis covering January 2025 through June 2026 shows prescription volumes for estrogen patches rose from 1.8 million to 3.6 million. While supply is increasing, it remains unknown when current production levels will meet the total domestic demand.
The players
Amneal
A pharmaceutical company that produces generic medications including hormone therapies.
Sandoz
A global pharmaceutical company focused on generic medicines and biosimilars.
Zydus
An international pharmaceutical firm that manufactures generic hormone replacement products.
Mylan/Viatris
A major pharmaceutical company that manufactures a wide range of generic healthcare products.
FDA
The federal agency responsible for regulating pharmaceutical labeling and monitoring drug supply chains.
The details
To address the market shortage, pharmaceutical companies have ramped up manufacturing and reallocated existing global supply chains to the U.S. market. While standardized patch production is increasing, compounding pharmacies are currently unable to manufacture the complex transdermal delivery systems required for these specific estrogen therapies, limiting the role of alternative sources in resolving the supply strain.
Timeline
January 2025: Prescription analysis window began.
February 2026: FDA issued updated labeling for estrogen therapy products.
June 2026: Prescription analysis window concluded.
September 2026: FDA identified increased demand for patches.
Health Landscape
The current supply efforts follow the FDA's 2026 estrogen therapy labeling update, which significantly influenced market demand. This shift highlights ongoing challenges in manufacturing complex transdermal delivery systems within the broader hormone replacement therapy market.
If you use estrogen patches, changes in supply can lead to unexpected gaps in your treatment plan. It is worth discussing current local availability and potential therapeutic alternatives with your physician to ensure your prescription remains uninterrupted.
The takeaway
Increased production from major manufacturers is currently underway to address the doubling of demand for estrogen patches. Patients experiencing difficulty filling prescriptions should maintain a proactive dialogue with their doctor regarding supply status and potential alternatives.
Further reading
For more information on managing your care during supply shifts, visit the Women’s Health section.
Source note: This article includes information reported by Drug Store News.
Live Poll
Should pharmaceutical companies be required to maintain specific supply levels for essential medications during demand spikes?
